Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 26, 2026.

The functional roles of the circRNA/Wnt axis in cancer

Chen Xue, Ganglei Li, Qiuxian Zheng and 4 more

Molecular Cancer · 2022 · Review · CC BY

doi:10.1186/s12943-022-01582-0

Abstract

CircRNAs, covalently closed noncoding RNAs, are widely expressed in a wide range of species ranging from viruses to plants to mammals. CircRNAs were enriched in the Wnt pathway. Aberrant Wnt pathway activation is involved in the development of various types of cancers. Accumulating evidence indicates that the circRNA/Wnt axis modulates the expression of cancer-associated genes and then regulates cancer progression. Wnt pathway-related circRNA expression is obviously associated with many clinical characteristics. CircRNAs could regulate cell biological functions by interacting with the Wnt pathway. Moreover, Wnt pathway-related circRNAs are promising potential biomarkers for cancer diagnosis, prognosis evaluation, and treatment. In our review, we summarized the recent research progress on the role and clinical application of Wnt pathway-related circRNAs in tumorigenesis and progression.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Background

Cancer is one of the main causes of death today and has become a serious public health problem worldwide. It is a complex disease that involves changes in a variety of processes, including genetic and epigenetic characteristic changes. The molecular changes in cancer genes and related signaling pathways could provide information for cancer diagnosis and targeted therapy. This information could contribute to improvements in cancer diagnosis and treatment.

Human genome sequence data indicate that more than 98% of the genome is noncoding genes. The transcripts of these genes lack protein-coding ability and are recognized as noncoding RNAs (ncRNAs). ncRNAs were once considered byproducts of transcription. With the development of high-throughput sequencing technology, ncRNA features have gradually been revealed. ncRNAs comprise various types of RNA species, including microRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs). CircRNA is a single-stranded, covalently closed ncRNA without 5’ end caps or 3’ end poly (A) tails. It is generated from its precursor mRNA by noncanonical splicing and is widely expressed in a wide range of species ranging from viruses to plants to mammals. circRNAs may act as transcription modulators, miRNA sponges, or protein decoys to exert their function in cancer progression. In addition, circRNAs are obviously associated with many clinical characteristics, which could provide important guidance for the accurate diagnosis and treatment of cancer. Accumulating evidence indicates that circRNAs play a pivotal role in the process of cancer and have the potential to be biomarkers in cancer diagnosis, prognosis, and treatment.

The Wnt pathway is an evolutionarily conserved pathway. It plays a critical role in embryonic development, tissue renewal and regeneration. The Wnt pathway can be divided into three classes: Wnt/β-catenin signaling, Wnt/planar cell polarity (PCP) signaling, and Wnt/Ca signaling. Aberrant activation of the Wnt pathway is significantly correlated with a series of cancers, such as lung cancer, colorectal cancer, bladder cancer, osteosarcoma, glioma, and chronic lymphocytic leukemia. Accumulating evidence indicates that circRNAs regulate a series of cellular biological functions by interacting with the Wnt pathway in the cancer process. These studies provided novel perspectives into cancer diagnosis and treatment. circRNAs related to the Wnt pathway have been the focus of many cancer research studies. In this review, we summarized the recent research progress regarding the molecular mechanisms and functional roles of circRNAs related to the Wnt pathway in tumorigenesis and tumor progression.

The wnt pathway in tumorigenesis

The Wnt gene was first identified in mouse mammary tumors in 1982. At that time, it was designated as int1. Because of the high homology between the mouse int1 gene and the Drosophila Wingless gene, the researchers merged Wingless with Int1 and assigned the name Wnt gene. The Wnt gene, localized at 12q13, mediates physiological effects in a paracrine and autocrine manner. The signaling pathways regulated by the Wnt gene are collectively termed the Wnt pathway. The Wnt signaling pathway is highly conserved from Drosophila to humans. The pathway is critical for a wide variety of cellular functions, such as cell polarity, movement, proliferation, asymmetric division, and muscle tissue development. Wnts are a family of secreted, lipid-modified proteins that bind to Frizzled receptors to activate signaling cascades. The Wnt pathway can be divided into three classes: Wnt/β-catenin signaling, Wnt/planar cell polarity signaling, and Wnt/Ca signaling (Fig. 1). Wnt/β-catenin signaling, a canonical Wnt signaling pathway, is involved in the regulation of gene expression. Wnt/planar cell polarity signaling regulates cell polarity and directional cell movements. Wnt/Ca signaling is obviously associated with the release of intracellular calcium. Dysregulation of the Wnt pathway has a strong relevance to cancer.

Wnt/β-catenin signaling

The Wnt/β-catenin signaling pathway is characterized by the cellular redistribution and nuclear accumulation of the β-catenin gene. Wnt protein combines with Frz and LRP5/6 on the cell surface to form a trimer, which transmits the signal and activates the protein Disheveled [Dsh/DVL]. This leads to the disassociation of the β-catenin degradation complex adenomatous polyposis coli (APC)/Axin/GSK-3β (glycogen synthase kinase 3β) and increases the cytoplasmic levels of β-catenin. Then, upregulated β-catenin is transferred into the nucleus. Nuclear β-catenin interacts with T cell transcription factor (TCF])/lymphoid enhancer factor (LEF) and finally activates the expression of downstream target genes. The Wnt/β-catenin signaling pathway participates in the cancer process by acting as an important modulator of cell proliferation, metastasis, and differentiation. Overexpression of the Wnt gene or mutation in one of the components that causes β-catenin degradation leads to activation of the Wnt/β-catenin pathway.

Wnt/PCP signaling

In the Wnt/PCP signaling pathway, Wnt binds to frizzled transmembrane receptors and then activates the protein Disheveled (Dsh/DVL), leading to a series of cell signaling cascades. DSH is connected to the downstream effectors Rho and ROCK (Rho-associated kinase) through Daam1. RAC is directly activated by Dsh, and Dsh further activates JNK by activating mitogen-activated protein kinases (MAP3Ks) and MAP2Ks. The PCP pathway is associated with cell polarity, cell alignment and cell migration.

Wnt/Ca 2 + signaling

In the Wnt/Ca 2 + pathway, the Wnt protein is mainly composed of Wnt1, Wnt5A and Wnt11 and binds to the Frizzled transmembrane receptor on the cell surface. The combination of the Wnt protein and Frizzled activates Disheveled, which activates PLC through the G protein. These cellular processes could finally promote the release of intracellular Ca2+. The activation of Disheveled could also activate the cGMP-specific phosphodiesterase PDE6 and reduce intracellular cGMP, which leads to an increase in the intracellular Ca2 + concentration. Elevated cytoplasmic Ca2 + concentrations can stimulate the nuclear factor NFAT and other transcription factors. These processes trigger the activation of downstream pathways and a series of altered cell functions. The Wnt/Ca2 + pathway is essential for early embryonic development, interneural communication and the inflammatory response.

CircRNA in the wnt pathway

CircRNAs, first found in the 1890s, remain enigmatic owing to technological limitations and limited existing knowledge. In 2013, Hansen TB et al. first proposed and confirmed that circRNAs function as miRNA sponges. This finding started a new era in circRNA research. Unlike linear RNAs, circRNAs are single-stranded, covalently closed noncoding RNAs without 5’ end caps or 3’ end poly (A) tails. CircRNAs are not affected by RNA exonuclease, and their expression is more stable. CircRNAs are formed by reverse splicing events. A mechanistic model argued that the RNA is partially folded during the transcription of pre-RNA. Initially, nonadjacent exons are pulled closer by RNA folding, and exon skipping occurs. The spanned region forms a circular RNA intermediate, and then circRNAs are formed by further splicing. Another model suggests that the reverse complement sequence located in the intron region causes the intron region to pair and mediate reverse splicing to form circRNA.

CircRNAs act mainly through four molecular mechanisms. In regulating gene expression, circRNAs affect the expression of parental gene mRNA by interacting with RNA binding proteins. Competitive complementary pairing between introns can strike a balance with linear RNAs during the formation of circRNAs. CircRNAs can also exert their functions by acting as competing endogenous RNAs (ceRNAs) of miRNAs. In addition, circRNAs are involved in the immune response. Endogenous circRNAs play a role in the antiviral response, while exogenous circRNAs can stimulate immune signaling in mammalian cells by activating the pattern recognition receptor RIG-L. Moreover, although circRNAs are noncoding RNAs, a few circRNAs can also perform regulatory functions by encoding peptides. Several previous studies have shown that circRNAs play an important role in tumorigenesis and tumor progression. CircRNA_403658 facilitates aerobic glycolysis and cell growth by upregulating LDHA expression in bladder cancer. CircRNA_103809 functions as an oncogene in the progression of hepatocellular carcinoma.

Both circRNAs and the Wnt pathway play a critical role in cancer development and progression. CircRNAs negatively or positively regulate cancer initiation, promotion, and progression by directly or indirectly interacting with the Wnt pathway. The interaction of circRNAs and the Wnt pathway has a noticeable impact on cell growth, metastasis, and other malignant cell behaviors in cancer. The majority of circRNAs act as sponges of miRNAs to activate or inactivate the Wnt pathway. With the deepening of research, more action modes between circRNAs and the Wnt pathway will be found. Related studies are expected to provide new insights for the diagnosis and treatment of cancer.

The role of the circRNA/Wnt axis in cancer

CircRNAs related to the Wnt pathway are aberrantly expressed in many cancers. Emerging evidence suggests that a range of clinical characteristics have been associated with circRNAs related to the Wnt pathway (Table 1). Moreover, the circRNA/Wnt axis contributes to cancer progression by modulating many cell biological functions. In this section, we will introduce the expression, corresponding clinical features, functions and mechanisms of the circRNAs/Wnt axis (Table 2).

Esophageal cancer

Elevated levels of circRNA_100367 were observed in radioresistant esophageal cancer cell lines, while the expression of cir-ITCH was downregulated in esophageal squamous cell carcinoma (ESCC) tissues (Fig. 2). The expression of cir-ITCH is positively associated with linear ITCH in ESCC. Functionally, colony formation and Cell Counting Kit-8 (CCK-8) assays showed that cir-ITCH could inhibit ESCC tumor growth through the regulation of cell proliferation. Knockdown of circRNA_100367 attenuates cell proliferation, migration, and radioresistance in esophageal cancer. circRNA_100367 decreases radiation sensitivity by regulating the miR-217/Wnt3 pathway. CircRNA_100367 could also affect esophageal cancer cell growth under irradiation in vivo. Using bioinformatics tools, Su et al. found that a large number of circRNAs were closely related to cancer progression. Further studies on these molecules are still required.

Gastric cancer

Some Wnt pathway-related circRNAs (circ0005654, circ-SFMBT2, circ_SMAD4, circRNA_0044516, and circHIPK3) are markedly upregulated in gastric cancer. The expression of circ0005654, circ_SMAD4, circHIPK3, and circheckd1 are positively associated with a poor prognosis in patients with gastric cancer. Functionally, these circRNAs all contribute to promoting tumor cell proliferation in gastric cancer. Additionally, circ0005654, circRNA_ASAP2, circ-SFMBT2, and circHIPK3 obviously promote gastric cancer cell migration and invasion. Circ-SFMBT2 upregulation indicates higher levels of oxidative stress in gastric cancer. Mechanistically, in vitro and in vivo studies demonstrated that circ0005654 functions as a ceRNA of miR-363 to upregulate sp1 in the process of gastric cancer. The level of CTNNB1 is regulated by circ-SFMBT2, a sponge of miR-1276. Circ-SFMBT2 activates the Wnt/β-catenin pathway by upregulating CTNNB1 expression. CircRNA_0044516 affects cancer progression by regulating the miR-149/Wnt1/β-catenin axis.

Interestingly, some researchers found that the expression of circCNIH4, cir-ITCH, and circ_0001649 was significantly downregulated in gastric cancer tissues and cells. cir-ITCH is closely related to lymph node metastasis and patient prognosis. CircCNIH4, cir-ITCH, and circ_0001649 markedly reduced cell proliferation, migration, and invasion in gastric cancer cell lines. CircCNIH4 and circ_0001649 also contribute to gastric cancer progression through the regulation of cell apoptosis. CircCNIH4 inhibits the Wnt/β-catenin pathway by upregulating DKK2 and FRZB levels (Fig. 3). Similarly, cir-ITCH reduce miR-17 levels to inactivate the Wnt/β-catenin pathway. Circ_0001649 inhibits the ERK and Wnt/β-catenin signaling pathways by sponging miR‐20a.

Colorectal cancer [CRC]

CircRNA dysregulation has been discovered to be closely related to the occurrence and progression of CRC. Wnt pathway-associated circRNAs of CRC are shown in Table 1. Circ_0082182, circ-PRKDC, circ5615, and circ_0005075 are significantly correlated with advanced tumor-node-metastasis (TNM) stage in CRC. The overexpression of circRASSF2, circ_0082182, circ5615, circcct3, circ_0005075, and circRNA_100290 indicates a poor prognosis in CRC patients. Circ-PRKDC is also associated with lymph node metastasis and tumor size. Circ_0005075 expression is correlated with differentiation and the depth of tumor invasion. Functionally, the expression of cis-HOX facilitates the self-renewal of colorectal tumor-initiating cells. Circ-ABCC1 could regulate malignant phenotypes, such as cell sphere formation ability, cell migration, and cell stemness, in CRC. The role of circ-PRKDC in 5-fluorouracil resistance has been reported. Additionally, the other Wnt pathway-associated upregulated circRNAs (Table 1) inhibit CRC cell growth and metastasis.

Liver cancer

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. The expression of circRNA-SORE, circβ-catenin, circZFR, and circ_0067934 is relatively elevated in HCC. In particular, increased circRNA-SORE levels were found in sorafenib-resistant HCC. CircZFR and circ_0067934 levels are significantly associated with the prognosis of patients with HCC. The expression of circ_0067934 is also markedly correlated with tumor TNM stage in HCC. CircRNA-SORE, cZNF292, circβ-catenin, circZFR, and circ_0067934 markedly facilitates cell proliferation. Additionally, cZNF292, circRNA-SORE, and circ_0067934 reduce cell apoptosis, while cZNF292 has no apparent effect on apoptosis. The overexpression of circβ-catenin, circZFR and circ_0067934 increased the migration or invasion of HCC cancer cells. High circRNA-SORE levels are important for maintaining HCC sorafenib resistance. Mechanistically, some circRNAs interact with Wnt/β-catenin via other molecules in HCC. Circ_0067934 regulates HCC cell behaviors by activating the miR-1324/FZD5/wnt/β-catenin axis. cZNF292 increases Wnt/β-catenin pathway activity through the upregulation of sex-determining region Y (SRY)-box 9 (SOX9) nuclear translocation.

On the other hand, the expression of circ_0004018, circ_0003418, and circ-ITCH is significantly downregulated in HCC. CircZKSCAN1 and circ-ITCH are potential prognostic biomarkers. Circ_0004018 and circ_0003418 are negatively correlated with tumor size. In addition, the expression of circ_0003418 has been reported to be related to TNM stage and HBsAg levels in HCC. Circ_0004018 and circ_0003418 contribute to cancer development and progression by regulating many cell biological functions, including cell proliferation, migration, and invasion. Knockdown of circZKSCAN1 could inhibit the malignant behaviors of HCC cancer stem cells, such as sphere formation, colony formation, cell proliferation, and metastasis. Circ_0004018 modulates the Wnt/β-catenin pathway to accelerate HCC progression by targeting the miR-626/DKK3 axis. CircZKSCAN1 binds with FMRP to increase Wnt signaling activity in HCC.

Pancreatic cancer

Pancreatic cancer is a digestive tract malignancy with limited treatment options and poor life expectancy. Pancreatic ductal adenocarcinoma is the most common primary malignancy of the pancreas. The expression of circ_0030167 is significantly elevated in bone marrow mesenchymal stem cells (BM-MSCs). Yao et al. isolated BM-MSCs from human bone marrow. circ_0030167, obtained from BM-MSC-derived exosomes, attenuates pancreatic cancer cell growth, metastasis, and stemness. Exosomal circ_0030167 activates the WIF1/Wnt8/β-catenin axis by sponging miR-338-5p in pancreatic cancer. An increasing number of Wnt pathway-associated circRNAs have also been found in pancreatic ductal adenocarcinoma. However, the underlying functions and mechanisms still need to be further explored.

Lung cancer

Lung cancer is the main cause of cancer-associated mortality worldwide. It can be classified into non-small-cell lung cancer (NSCLC) and small-cell lung cancer, and NSCLC accounts for the overwhelming majority of lung cancer cases. Wnt pathway-associated circRNAs of NSCLC are shown in Table 1 (Fig. 4). The overexpression of circ_000984 and circ_001569 is significantly correlated with TNM stage and lymph node metastasis in NSCLC. The circ_0001946 expression profile is obviously associated with TNM stage and tumor size in NSCLC. Additionally, circ_000984, circ_001569, and circ_0001946 upregulation predicts a poor prognosis in patients with NSCLC. These upregulated circRNAs in NSCLC could promote cell growth by enhancing cell proliferation. In vitro astray assays showed that silencing circ_0067934 and circ_000984 could inhibit the epithelial-mesenchymal transition (EMT) process to reduce cell metastasis in NSCLC. Circ-PGC could also hinder cancer progression by suppressing glycolysis metabolism. Mechanistically, the majority of circRNAs interact with miRNAs to activate the Wnt/β-catenin pathway in NSCLC.

Interestingly, circ_0018414, circ_0006427, circ_0007059, and cir-ITCH are remarkably downregulated in NSCLC. Circ_0018414 and circ_0006427 are markedly associated with the overall survival rate. Circ_0006427 and circ_0007059 facilitate cell growth and motility in NSCLC. Circ_0018414 enhances stemness features by promoting DKK1 expression in NSCLC (Fig. 5). CircRNAs can inhibit NSCLC tumorigenesis and progression by regulating the circ_0018414/miR-6807-3p/dkk1/Wnt/β-catenin, circ_0006427/ miR-6783-3p/dkk1/Wnt/β-catenin, and circ_0007059/miR-378/Wnt/β-catenin pathways and the cir-ITCH/miR-7/miR-214/ITCH/Wnt/β-catenin axis.

Glioma

Malignant gliomas are the most common primary tumors of the central nervous system. Wnt pathway-associated circRNAs have drawn much attention in glioma research in recent years. The levels of circ_0001730, circKIF4A, circ_0000177, and cZNF292 are upregulated in glioma tissues versus normal brain tissues. Circ_0000177 is related to clinical stage, and patients with increased circ_0000177 expression have a poor prognosis. Circ_0001730, circKIF4A, and circ_0000177 are all involved in tumor cell growth and metastasis in glioma. cZNF292 promotes cancer development by regulating cell proliferation, the cell cycle, and angiogenesis. Mechanistically, circ_0001730 functions as a sponge of miR-326 to positively regulate Wnt/β-catenin pathways in the pathophysiologic processes of glioma. Circ_0001730 could also be upregulated by SP1. Overexpression of circ_0000177 increases FZD7 levels to activate Wnt signaling mediated by miR-638 in glioma.

Prostate cancer (PCa)

PCa refers to an epithelial malignancy that occurs in the prostate. The expression of cir-ITCH was significantly downregulated in PCa tissues and cell lines. Further experiments showed that cir-ITCH could attenuate PCa cell viability and invasion. Cir-ITCH hinders PCa development by inactivating the Wnt/β-Catenin and PI3K/AKT/mTOR pathways. Not much is known about Wnt pathway-associated circRNAs in PCa. There is a crucial need for Wnt pathway-associated circRNA research in PCa.

Female reproductive system cancers

Cancers that originate in the female reproductive system are called female reproductive cancers. Ovarian cancer (OC), endometrial cancer (EC), and cervical cancer are the three most common gynecological malignancies. The expression of circ‑ABCB10 is significantly upregulated, while circPLEKHM3 expression is downregulated in OC. Moreover, the level of circPLEKHM3 is positively associated with the overall survival rate in patients with OC. Circ‑ABCB10 remarkably facilitates cell proliferation and invasion and reduces cell apoptosis by miR-1271 in OC. Circ‑ABCB10 plays a critical role in OC progression via the regulation of Capn4/Wnt/β‑catenin. CircPLEKHM3 inhibits cell proliferation and migration by sponging miR-9 and regulating the BRCA1/DNAJB6/KLF4/AKT1/Wnt/β-catenin axis in OC. Circ_0109046 and circ_0002577 are elevated in EC tissues and cell lines. The overexpression of circ_0002577 is positively correlated with advanced FIGO stage and lymph node metastasis in EC. High expression of circ_0109046 and circ_0002577 predicts a poor prognosis in patients with EC. Circ_0109046 activates the Wnt/β-catenin pathway by sponging miR-105 to increase SOX9 levels. Circ_0002577 functions as a sponge of miR-197 to regulate the CTNND1/Wnt/β-catenin axis in EC. CircSAMD11 expression is markedly upregulated in cervical cancer. Silencing of circSAMD11 expression suppressed cell proliferation and metastasis and promoted cell apoptosis in cervical cancer. The circSAMD11/miR-503/sox4/Wnt/β-catenin axis plays an essential role in the progression of cervical cancer.

Tumors of the blood system

Hematological malignancies, also known as neoplasms of the blood, lymph nodes and bone marrow, include leukemia, lymphoma, and multiple myeloma. The common types of leukemia are acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Circ_0121582 expression is significantly decreased in AML. Functional experiments demonstrated that the overexpression of circ_0121582 significantly attenuated cell survival and promoted the cell cycle arrest in AML. Circ_0121582 activates Wnt/β-catenin by sponging miR-224 to increase GSK3β expression in AML. The expression of circ-CBFB was upregulated in CLL, and it has been reported as an independent predictive factor for the prognosis of CLL. Circ-CBFB facilitates CLL cell proliferation and inhibits cell apoptosis by sponging miR-607 and upregulating the FZD3/Wnt/β-catenin axis. Diffuse large B-cell lymphoma (DLBCL) is the most common malignant lymphoma subtype. The level of circ-APC is significantly decreased in the tissues, cell lines, and plasma of DLBCL patients versus normal controls. circ-APC inactivates the Wnt/β-catenin pathway to suppress cell proliferation in DLBCL through the regulation of the miR-888/APC and TET1/APC axes.

Osteosarcoma (OS)

OS is the most common primary malignant neoplasm of the bone and mainly affects children, adolescents, and young adults. The level of circMYO10 is significantly elevated, while circ_0002052 expression is downregulated in OS tissues and cell lines. The expression of circ_0002052 is positively associated with overall and progression-free survival in patients with OS. circ_0002052 inhibits cell growth and cell motility and enhances cell apoptosis in OS by sponging miR-1205 and modulating the APC2/Wnt/β-catenin axis. CircMYO10 functions as an oncogene in OS progression. The overexpression of circMYO10 facilitates OS cell proliferation and EMT in vitro. CircMYO10 facilitates histone H4K16 acetylation by regulating the miR-370-3p/RUVBL1 axis and activating Wnt/β-catenin signaling in OS. Cisplatin (DDP) is a conventional chemotherapy drug in the treatment of OS. Cisplatin resistance is a major challenge for OS chemotherapy application. CircUBAP2 expression is increased in cisplatin-resistant OS tissues and cells. Silencing circUBAP2 inhibits cell proliferation, migration, and invasion and induced apoptosis in OS. CircUBAP2 knockdown also suppresses cisplatin resistance by regulating miR-506-3p/SEMA6D and the Wnt/β-catenin pathway.

Thyroid cancer

The incidence rate of thyroid cancer has been increasing throughout the world. CircRNA_102171 and circRNA_NEK6 are relatively upregulated, while circ-ITCH is downregulated in thyroid cancer tissues and cell lines. The level of circ-ITCH is closely associated with clinical stage, lymph node metastasis, and patient prognosis in thyroid cancer. CircRNA_102171 and circRNA_NEK6 play a promoting role in cell growth and metastasis. CircRNA_102171 activates the Wnt/β-catenin pathway in a CTNNBIP1-dependent way. CircRNA_NEK6 facilitates thyroid cancer progression by sponging miR-370-3p and upregulating the FZD8/Wnt axis. Circ-ITCH exerts its tumor suppressor action by modulating miR-22-3p/CBL/β-catenin in thyroid cancer.

Tumors of other systems

Breast cancer is one of the most common malignant malignancies among females worldwide. Circ-EIF6, circARL8B, circABCC4, circRNA_069718, and circFAT1 expression levels are obviously upregulated in breast cancer. CircRNA_069718 overexpression is positively correlated with TNM stage, lymph node metastasis, and overall survival in patients with breast cancer. These upregulated Wnt-associated circRNAs contribute to cancer progression by promoting cell growth and metastasis. In addition, studies also observed that knockdown of circARL8B could induce a suppressive effect on fatty acid metabolism in breast cancer. CircFAT1 enhances oxaliplatin resistance through the miR-525-5p/SKA1 and Wnt pathways in breast cancer. CircARL8B, circABCC4, and CircFAT1 regulate the Wnt pathway by acting as sponges of miRNAs in breast cancer. EIF6-224aa, encoded by circ-EIF6, activates Wnt/β-catenin by regulating the MYH9/Wnt/beta-catenin pathway.

Melanoma is a potentially fatal disease with increasing incidence. Circ_0027247 was isolated from circ-GLI1. Circ_0119872, circ_0084043 and circ-GLI1 (circ_0027247) are dramatically upregulated in melanoma tissues and cell lines. High levels of circ_0027247 and circ_0084043 can promote cell motility, while circ_0119872 has no influence on cell migration and invasion. Circ_0119872 and circ_0027247 are novel negative feedback regulators of angiogenesis in melanoma. Circ_0119872 and circ_0084043 have the same effects on cell proliferation. Circ_0119872 activates the Wnt/β-catenin pathway by interacting with p70S6K2 and upregulates Cyr61 expression in melanoma. The tumorigenesis and progression of melanoma are also regulated by the circ_0119872/ p70S6K2/Wnt/β-catenin and circ_0027247/miR-622/G3BP1/Wnt/β-catenin axes.

CircRNA, a potential biomarker in wnt pathway

Despite technological advances, cancer diagnosis and treatment are still a challenge that may require the emergence of new tumor biomarkers. Increasing evidence has revealed that Wnt-associated circRNAs are closely related to cancer progression. Wnt-associated circRNAs may be very promising biomarkers in cancer diagnosis, prognosis, and treatment. In this section, we will further discuss their potential application in clinical practice.

Diagnosis

The early screening and diagnosis of cancer is conducive to the survival of cancer patients. Identifying suitable biomarkers has always been a difficult issue in cancer research. Wnt-associated circRNAs may be used to assist early diagnosis in many cancers. They are aberrantly expressed in many kinds of tumors from multiple systems, such as digestive tumors, respiratory system tumors, nervous system neoplasms, genitourinary tumors, musculoskeletal system tumors and endocrine system cancers. Moreover, plasma circ-APC levels are significantly downregulated in DLBCL. This discovery indicates a more convenient clinical application of circ-APC as a diagnostic marker. Studies further evaluated the diagnostic potential for cancer by receiver operating characteristic (ROC) curve analysis. Yang et al. found that the AUC value of circ0005654 was 0.781 in gastric cancer. ROC analysis of circRASSF2 expression levels in colorectal cancer tissues and cells accurately discriminated between CRC patients and healthy controls (AUC: 0.9863). Further experimental verification and research on circRASSF2 in body fluids is necessary. The corresponding AUC value for circ-CBFB was 0.80 in chronic lymphocytic leukemia.

Prognosis prediction

Early prognostic information is important in making treatment decisions. A growing amount of evidence shows that Wnt-associated circRNAs can be of important prognostic value. These circRNAs are closely related to overall survival, disease-free survival, recurrence-free survival, 5-year survival rate, and progression-free survival in several cancers. Patients with lower circZKSCAN1 expression have shorter overall and recurrence-free survival in HCC. Li et al. reported that the overexpression of circCCT3 was negatively correlated with the disease-free survival rate in colorectal cancer. Higher circ_0109046 expression predicts a decreased 5-year survival rate in patients with endometrial carcinoma. Such studies have important implications in prognosis evaluation and treatment selection. In addition, Wnt-associated circRNAs are associated with other relevant prognostic factors. For example, downregulated circMTO1 levels predict advanced TNM stage and lymph node metastasis in CRC.

Cancer treatment

Despite rapidly progressing treatment modalities, cancer therapy remains one of the most challenging issues in the world. CircRNA-based targeted therapeutic strategies shed new light on the evolution of cancer treatment. CircRNAs regulate many cell biological functions by directly or indirectly interacting with the Wnt pathway. CircRNA_NEK6 activated the FZD8/Wnt axis to facilitate thyroid cancer progression by sponging miR-370-3p. Circ_0121582 promotes GSK3β expression to activate the Wnt/β-catenin pathway by sponging miR-224 in AML. Circ-SFMBT2 contributes to the development and tumorigenesis of gastric cancer via regulation of the miR-1276/CTNNB1/Wnt/β-catenin axis. Controlling Wnt-associated circRNA expression may be an effective approach for cancer treatment. The knockdown of circ_SMAD4 blocked gastric cancer progression by negatively regulating cell growth. Silencing circ-ZNF124 expression inhibited malignant phenotypes in NSCLC cells. In addition, Circ-ITCH is a tumor suppressor in many cancers. Wang et al. found that upregulated circ-ITCH expression suppressed cell proliferation and invasion in papillary thyroid cancer. However, the identification of targeted drugs that can stably control the expression of circRNA and transmit this effect is the current difficulty. This requires a deeper understanding of the structure and function of Wnt-associated circRNAs. The majority of circRNAs act as sponges of miRNAs to activate or inactivate the Wnt pathway. Regulating the target miRNAs of Wnt-associated circRNAs may also be feasible. MiR-582 intervention effectively reversed the cell biological functions regulated by circ_0009361 in CRC.

Conclusions and future perspectives

The Wnt signaling pathway is highly involved in cancer development, and essential for a wide variety of cellular functions, such as cell polarity, movement, proliferation, asymmetric division, and muscle tissue development. Both circRNA and the Wnt pathway play a critical role in cancer development and progression. Emerging data suggest that the circRNA/Wnt axis modulates the expression of cancer-associated genes and then regulates tumor progression. CircRNAs are enriched in the Wnt pathway. Wnt-associated circRNAs are abnormally expressed in digestive tumors, respiratory system tumors, nervous system neoplasms, genitourinary tumors, musculoskeletal system tumors, endocrine system cancers and other cancers. Their aberrant expression indicates their potential as diagnostic markers. However, most related experiments are based on tissue and cell research. Ideal and effective molecular markers should be stably expressed in plasma, serum, and other body fluids. Such molecules have greater potential for clinical applications. Wnt-associated circRNAs are also promising potential biomarkers in the treatment of cancer. CircRNAs negatively or positively regulate cancer initiation, promotion, and progression by directly or indirectly interacting with the Wnt pathway. We could enhance the expression of cancer-promoting circRNAs or inhibit the expression of tumor suppressor circRNAs to control cancer progression. The current goal is to find targeted drugs that can stably control the expression of circRNA and induce this effect. We need to further understand the structure and function of Wnt-related circRNAs. Furthermore, the interaction and the related mechanisms between circRNAs involved in the Wnt pathway need more studies to confirm.

References 323

  1. 1.

    Siegel RL, Sahar L, Portier KM, Ward EM, Jemal A. Cancer death rates in US congressional districts. CA Cancer J Clin. 2015;65::339-44.

    Not in our library10.3322/caac.21292

  2. 2.

    Siegel RL, Miller KD, Jemal A. Cancer statistics. 2020. CA Cancer J Clin. 2020;70:7–30. 10.3322/caac.21590.

    Not in our library10.3322/caac.21590

  3. 3.

    Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71::264-79.

    Not in our library10.3322/caac.21657

  4. 4.

    Rinaldi F, Hanieh PN, Del Favero E, Rondelli V, Brocca P, Pereira MC, et al. Decoration of Nanovesicles with pH (Low) Insertion Peptide (pHLIP) for Targeted Delivery. Nanoscale Res Lett. 2018;13::391.

    Not in our library10.1186/s11671-018-2807-8

  5. 5.

    Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493-502.

    Not in our library10.1038/s41575-021-00457-x

  6. 6.

    Zhou S, Treloar AE, Lupien M. Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations. Cancer Discov. 2016;6::1215-29.

    Not in our library10.1158/2159-8290.cd-16-0745

  7. 7.

    Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. 2020;17:91-107.

    Not in our library10.1038/s41571-019-0267-4

  8. 8.

    van der Pol Y, Mouliere F. Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. Cancer Cell. 2019;36::350-68.

    Not in our library10.1016/j.ccell.2019.09.003

  9. 9.

    Calses PC, Crawford JJ, Lill JR, Dey A. Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. Trends Cancer. 2019;5:297-307.

    Not in our library10.1016/j.trecan.2019.04.001

  10. 10.
  11. 11.

    Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26::3279-90.

    Not in our library10.1038/sj.onc.1210421

  12. 12.

    Engreitz JM, Haines JE, Perez EM, Munson G, Chen J, Kane M, et al. Local regulation of gene expression by lncRNA promoters, transcription and splicing. Nature. 2016;539::452-5.

    Not in our library10.1038/nature20149

  13. 13.
  14. 14.

    Saw PE, Xu X, Chen J, Song EW. Non-coding RNAs: the new central dogma of cancer biology. Sci China Life Sci. 2021;64:22-50.

    Not in our library10.1007/s11427-020-1700-9

  15. 15.

    Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16::167-79.

    Not in our library10.1038/nrd.2016.117

  16. 16.

    Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10::155-9.

    Not in our library10.1038/nrg2521

  17. 17.

    Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006;15 Spec No 1:R17–29. 10.1093/hmg/ddl046.

    Not in our library10.1093/hmg/ddl046

  18. 18.

    Li G, Zhang T, Huang K, Zhu Y, Xu K, Gu J, et al. Long noncoding RNA GAS8-AS1: A novel biomarker in human diseases. Biomed Pharmacother. 2021;139::111572.

    Not in our library10.1016/j.biopha.2021.111572

  19. 19.

    Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18:5-18.

    Not in our library10.1038/nrc.2017.99

  20. 20.

    Wright MW, Bruford EA. Naming ‘junk’: human non-protein coding RNA (ncRNA) gene nomenclature. Hum Genomics. 2011;5::90-8.

    Not in our library10.1186/1479-7364-5-2-90

  21. 21.
  22. 22.

    Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol Rev. 2016;96::1297-325.

    Not in our library10.1152/physrev.00041.2015

  23. 23.
  24. 24.

    Zhu KP, Zhang CL, Ma XL, Hu JP, Cai T, Zhang L. Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. Mol Ther. 2019;27::518-30.

    Not in our library10.1016/j.ymthe.2019.01.001

  25. 25.
  26. 26.
  27. 27.

    Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Wu M. Epigenetics in Neurodevelopment: Emerging Role of Circular RNA. Front Cell Neurosci. 2019;13::327.

    Not in our library10.3389/fncel.2019.00327

  28. 28.
  29. 29.

    Chen X, Yang T, Wang W, Xi W, Zhang T, Li Q, et al. Circular RNAs in immune responses and immune diseases. Theranostics. 2019;9:588-607.

    Not in our library10.7150/thno.29678

  30. 30.

    Conn VM, Hugouvieux V, Nayak A, Conos SA, Capovilla G, Cildir G, et al. A circRNA from SEPALLATA3 regulates splicing of its cognate mRNA through R-loop formation. Nat Plants. 2017;3::17053.

    Not in our library10.1038/nplants.2017.53

  31. 31.

    Jiang JY, Ju CJ, Hao J, Chen M, Wang W. JEDI: circular RNA prediction based on junction encoders and deep interaction among splice sites. Bioinformatics. 2021;37:i289-i98.

    Not in our library10.1093/bioinformatics/btab288

  32. 32.
  33. 33.

    Zhou J, Ge Y, Hu Y, Rong D, Fu K, Wang H, et al. Circular RNAs as novel rising stars with huge potentials in development and disease. Cancer Biomark. 2018;22:597-610.

    Not in our library10.3233/cbm-181296

  34. 34.

    Dong W, Dai ZH, Liu FC, Guo XG, Ge CM, Ding J, et al. The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production. EBioMedicine. 2019;45:155-67.

    Not in our library10.1016/j.ebiom.2019.06.030

  35. 35.

    Wang L, Yi J, Lu LY, Zhang YY, Wang L, Hu GS, et al. Estrogen-induced circRNA, circPGR, functions as a ceRNA to promote estrogen receptor-positive breast cancer cell growth by regulating cell cycle-related genes. Theranostics. 2021;11::1732-52.

    Not in our library10.7150/thno.45302

  36. 36.

    He D, Yang X, Kuang W, Huang G, Liu X, Zhang Y. The Novel Circular RNA Circ-PGAP3 Promotes the Proliferation and Invasion of Triple Negative Breast Cancer by Regulating the miR-330-3p/Myc Axis. Onco Targets Ther. 2020;13::10149-59.

    Not in our library10.2147/ott.s274574

  37. 37.
  38. 38.

    Zeng K, Wang S, Circular, RNAs. The crucial regulatory molecules in colorectal cancer. Pathol Res Pract. 2020;216::152861.

    Not in our library10.1016/j.prp.2020.152861

  39. 39.

    Liu P, Zou Y, Li X, Yang A, Ye F, Zhang J, et al. circGNB1 Facilitates Triple-Negative Breast Cancer Progression by Regulating miR-141-5p-IGF1R Axis. Front Genet. 2020;11::193.

    Not in our library10.3389/fgene.2020.00193

  40. 40.
  41. 41.

    Li Y, Shi P, Zheng T, Ying Z, Jiang D. Circular RNA hsa_circ_0131242 Promotes Triple-Negative Breast Cancer Progression by Sponging hsa-miR-2682. Onco Targets Ther. 2020;13::4791-8.

    Not in our library10.2147/ott.s246957

  42. 42.
  43. 43.
  44. 44.

    Szabo L, Salzman J. Detecting circular RNAs: bioinformatic and experimental challenges. Nat Rev Genet. 2016;17::679-92.

    Not in our library10.1038/nrg.2016.114

  45. 45.
  46. 46.

    Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The Landscape of Circular RNA in Cancer. Cell 2019;176:869 – 81.e13. 10.1016/j.cell.2018.12.021.

    Not in our library10.1016/j.cell.2018.12.021

  47. 47.
  48. 48.
  49. 49.

    Schunk SJ, Floege J, Fliser D, Speer T. WNT-β-catenin signalling - a versatile player in kidney injury and repair. Nat Rev Nephrol. 2021;17::172-84.

    Not in our library10.1038/s41581-020-00343-w

  50. 50.

    Bengoa-Vergniory N, Kypta RM. Canonical and noncanonical Wnt signaling in neural stem/progenitor cells. Cell Mol Life Sci. 2015;72::4157-72.

    Not in our library10.1007/s00018-015-2028-6

  51. 51.

    Mah AT, Yan KS, Kuo CJ. Wnt pathway regulation of intestinal stem cells. J Physiol. 2016;594::4837-47.

    Not in our library10.1113/jp271754

  52. 52.

    Blagodatski A, Klimenko A, Jia L, Katanaev VL. Small Molecule Wnt Pathway Modulators from Natural Sources: History, State of the Art and Perspectives. Cells 2020;9. 10.3390/cells9030589.

    Not in our library10.3390/cells9030589

  53. 53.
  54. 54.

    Camilli TC, Weeraratna AT. Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression. Biochem Pharmacol 2010;80:702 – 11. 10.1016/j.bcp.2010.03.002.

    Not in our library10.1016/j.bcp.2010.03.002

  55. 55.
  56. 56.
  57. 57.

    Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett. 2005;222:1-10.

    Not in our library10.1016/j.canlet.2004.08.040

  58. 58.
  59. 59.
  60. 60.

    Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol. 2019;75::423-32.

    Not in our library10.1016/j.eururo.2018.08.027

  61. 61.

    Zhan Y, Zhang L, Yu S, Wen J, Liu Y, Zhang X. Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/β-catenin signaling pathway in bladder cancer. J Exp Clin Cancer Res. 2020;39::136.

    Not in our library10.1186/s13046-020-01624-9

  62. 62.

    Matsuoka K, Bakiri L, Wolff LI, Linder M, Mikels-Vigdal A, Patiño-García A, et al. Wnt signaling and Loxl2 promote aggressive osteosarcoma. Cell Res. 2020;30::885-901.

    Not in our library10.1038/s41422-020-0370-1

  63. 63.
  64. 64.

    Yue X, Lan F, Xia T. Hypoxic Glioma Cell-Secreted Exosomal miR-301a Activates Wnt/β-catenin Signaling and Promotes Radiation Resistance by Targeting TCEAL7. Mol Ther. 2019;27::1939-49.

    Not in our library10.1016/j.ymthe.2019.07.011

  65. 65.
  66. 66.
  67. 67.

    Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:3118-23.

    Not in our library10.1073/pnas.0308648100

  68. 68.
  69. 69.

    Gao N, Ye B. Circ-SOX4 drives the tumorigenesis and development of lung adenocarcinoma via sponging miR-1270 and modulating PLAGL2 to activate WNT signaling pathway. Cancer Cell Int. 2020;20::2.

    Not in our library10.1186/s12935-019-1065-x

  70. 70.

    Ge Z, Li LF, Wang CY, Wang Y, Ma WL. CircMTO1 inhibits cell proliferation and invasion by regulating Wnt/β-catenin signaling pathway in colorectal cancer. Eur Rev Med Pharmacol Sci. 2018;22::8203-9.

    Not in our library10.26355/eurrev_201812_16513

  71. 71.
  72. 72.

    He J, Xie Q, Xu H, Li J, Li Y. Circular RNAs and cancer. Cancer Lett 2017;396:138 – 44. 10.1016/j.canlet.2017.03.027.

    Not in our library10.1016/j.canlet.2017.03.027

  73. 73.

    Wang L, Li B, Yi X, Xiao X, Zheng Q, Ma L. Circ_SMAD4 promotes gastric carcinogenesis by activating wnt/β-catenin pathway. Cell Prolif. 2021;54:e12981.

    Not in our library10.1111/cpr.12981

  74. 74.

    Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31:99-109.

    Not in our library10.1016/0092-8674(82)90409-3

  75. 75.

    Chen X, Yang J, Evans PM, Liu C. Wnt signaling: the good and the bad. Acta Biochim Biophys Sin (Shanghai). 2008;40:577 – 94. 10.1111/j.1745-7270.2008.00440.x.

    Not in our library10.1111/j.1745-7270.2008.00440.x

  76. 76.

    Korzh V. Winding roots of Wnts. Zebrafish. 2008;5:159-68.

    Not in our library10.1089/zeb.2008.0532

  77. 77.

    Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469 – 80. 10.1016/j.cell.2006.10.018.

    Not in our library10.1016/j.cell.2006.10.018

  78. 78.

    Perochon J, Carroll LR, Cordero JB. Wnt Signalling in Intestinal Stem Cells: Lessons from Mice and Flies. Genes (Basel). 2018;9. 10.3390/genes9030138.

    Not in our library10.3390/genes9030138

  79. 79.
  80. 80.

    Hayashi K, Erikson DW, Tilford SA, Bany BM, Maclean JA, Rucker EB. Wnt genes in the mouse uterus: potential regulation of implantation. Biol Reprod. 2009;80:989-1000.

    Not in our library10.1095/biolreprod.108.075416

  81. 81.

    Poindexter KM, Matthew S, Aronchik I, Firestone GL. Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells. Cell Biol Toxicol. 2016;32:103-19.

    Not in our library10.1007/s10565-016-9321-5

  82. 82.

    Su X, Zhao Y, Wang Y, Zhang L, Zan L, Wang H. Overexpression of the Rybp Gene Inhibits Differentiation of Bovine Myoblasts into Myotubes. Int J Mol Sci 2018;19. 10.3390/ijms19072082.

    Not in our library10.3390/ijms19072082

  83. 83.

    Vladar EK, Königshoff M. Noncanonical Wnt planar cell polarity signaling in lung development and disease. Biochem Soc Trans. 2020;48::231-43.

    Not in our library10.1042/bst20190597

  84. 84.

    Tan Y, Yu D, Busto GU, Wilson C, Davis RL. Wnt signaling is required for long-term memory formation. Cell Rep. 2013;4::1082-9.

    Not in our library10.1016/j.celrep.2013.08.007

  85. 85.

    Cerpa W, Farías GG, Godoy JA, Fuenzalida M, Bonansco C, Inestrosa NC. Wnt-5a occludes Abeta oligomer-induced depression of glutamatergic transmission in hippocampal neurons. Mol Neurodegener. 2010;5::3.

    Not in our library10.1186/1750-1326-5-3

  86. 86.

    Pandit AA, Gandham RK, Mukhopadhyay CS, Verma R, Sethi RS. Transcriptome analysis reveals the role of the PCP pathway in fipronil and endotoxin-induced lung damage. Respir Res. 2019;20::24.

    Not in our library10.1186/s12931-019-0986-1

  87. 87.
  88. 88.

    Van Steenwinckel J, Schang AL, Krishnan ML, Degos V, Delahaye-Duriez A, Bokobza C, et al. Decreased microglial Wnt/β-catenin signalling drives microglial pro-inflammatory activation in the developing brain. Brain. 2019;142:3806-33.

    Not in our library10.1093/brain/awz319

  89. 89.

    Murillo-Garzón V, Gorroño-Etxebarria I, Åkerfelt M, Puustinen MC, Sistonen L, Nees M, et al. Frizzled-8 integrates Wnt-11 and transforming growth factor-β signaling in prostate cancer. Nat Commun. 2018;9::1747.

    Not in our library10.1038/s41467-018-04042-w

  90. 90.

    Ueno A, Masugi Y, Yamazaki K, Komuta M, Effendi K, Tanami Y, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61::1080-7.

    Not in our library10.1016/j.jhep.2014.06.008

  91. 91.

    Tawk M, Makoukji J, Belle M, Fonte C, Trousson A, Hawkins T, et al. Wnt/beta-catenin signaling is an essential and direct driver of myelin gene expression and myelinogenesis. J Neurosci. 2011;31::3729-42.

    Not in our library10.1523/jneurosci.4270-10.2011

  92. 92.

    Niell N, Larriba MJ, Ferrer-Mayorga G, Sánchez-Pérez I, Cantero R, Real FX, et al. The human PKP2/plakophilin-2 gene is induced by Wnt/β-catenin in normal and colon cancer-associated fibroblasts. Int J Cancer. 2018;142:792-804.

    Not in our library10.1002/ijc.31104

  93. 93.

    Kaucká M, Petersen J, Janovská P, Radaszkiewicz T, Smyčková L, Daulat AM, et al. Asymmetry of VANGL2 in migrating lymphocytes as a tool to monitor activity of the mammalian WNT/planar cell polarity pathway. Cell Commun Signal. 2015;13::2.

    Not in our library10.1186/s12964-014-0079-1

  94. 94.

    Babayeva S, Rocque B, Aoudjit L, Zilber Y, Li J, Baldwin C, et al. Planar cell polarity pathway regulates nephrin endocytosis in developing podocytes. J Biol Chem. 2013;288::24035-48.

    Not in our library10.1074/jbc.m113.452904

  95. 95.

    Vargas JY, Loria F, Wu YJ, Córdova G, Nonaka T, Bellow S, et al. The Wnt/Ca(2+) pathway is involved in interneuronal communication mediated by tunneling nanotubes. Embo j. 2019;38:e101230.

    Not in our library10.15252/embj.2018101230

  96. 96.

    Thrasivoulou C, Millar M, Ahmed A. Activation of intracellular calcium by multiple Wnt ligands and translocation of β-catenin into the nucleus: a convergent model of Wnt/Ca2 + and Wnt/β-catenin pathways. J Biol Chem. 2013;288::35651-9.

    Not in our library10.1074/jbc.m112.437913

  97. 97.

    Jamieson C, Lui C, Brocardo MG, Martino-Echarri E, Henderson BR. Rac1 augments Wnt signaling by stimulating β-catenin-lymphoid enhancer factor-1 complex assembly independent of β-catenin nuclear import. J Cell Sci. 2015;128::3933-46.

    Not in our library10.1242/jcs.167742

  98. 98.
  99. 99.

    Henson JH, Samasa B, Shuster CB, Wikramanayake AH. The nanoscale organization of the Wnt signaling integrator Dishevelled in the vegetal cortex domain of an egg and early embryo. PLoS One. 2021;16:e0248197.

    Not in our library10.1371/journal.pone.0248197

  100. 100.

    Guo J, Cagatay T, Zhou G, Chan CC, Blythe S, Suyama K, et al. Mutations in the human naked cuticle homolog NKD1 found in colorectal cancer alter Wnt/Dvl/beta-catenin signaling. PLoS One. 2009;4:e7982.

    Not in our library10.1371/journal.pone.0007982

  101. 101.

    Ji L, Lu B, Wang Z, Yang Z, Reece-Hoyes J, Russ C, et al. Identification of ICAT as an APC Inhibitor, Revealing Wnt-Dependent Inhibition of APC-Axin Interaction. Mol Cell. 2018;72::37-47.e4.

    Not in our library10.1016/j.molcel.2018.07.040

  102. 102.

    Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012;149:1192 – 205. 10.1016/j.cell.2012.05.012.

    Not in our library10.1016/j.cell.2012.05.012

  103. 103.

    Doumpas N, Lampart F, Robinson MD, Lentini A, Nestor CE, Cantù C, et al. TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes. Embo j 2019;38. 10.15252/embj.201798873.

    Not in our library10.15252/embj.201798873

  104. 104.

    Danek P, Kardosova M, Janeckova L, Karkoulia E, Vanickova K, Fabisik M, et al. β-Catenin-TCF/LEF signaling promotes steady-state and emergency granulopoiesis via G-CSF receptor upregulation. Blood. 2020;136:2574-87.

    Not in our library10.1182/blood.2019004664

  105. 105.

    Fu X, Zhu X, Qin F, Zhang Y, Lin J, Ding Y, et al. Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. Mol Cancer. 2018;17::73.

    Not in our library10.1186/s12943-018-0783-3

  106. 106.

    Huang K, Zhang JX, Han L, You YP, Jiang T, Pu PY, et al. MicroRNA roles in beta-catenin pathway. Mol Cancer. 2010;9::252.

    Not in our library10.1186/1476-4598-9-252

  107. 107.
  108. 108.

    Jo S, Yoon S, Lee SY, Kim SY, Park H, Han J, et al. DKK1 Induced by 1,25D3 Is Required for the Mineralization of Osteoblasts. Cells 2020;9. 10.3390/cells9010236.

    Not in our library10.3390/cells9010236

  109. 109.

    Yu JJS, Maugarny-Calès A, Pelletier S, Alexandre C, Bellaiche Y, Vincent JP, et al. Frizzled-Dependent Planar Cell Polarity without Secreted Wnt Ligands. Dev Cell 2020;54:583 – 92.e5. 10.1016/j.devcel.2020.08.004.

    Not in our library10.1016/j.devcel.2020.08.004

  110. 110.

    Rogers S, Scholpp S. Vertebrate Wnt5a - At the crossroads of cellular signalling. Semin Cell Dev Biol. 2021;125:3-10.

    Not in our library10.1016/j.semcdb.2021.10.002

  111. 111.

    Lapébie P, Borchiellini C, Houliston E. Dissecting the PCP pathway: one or more pathways?: Does a separate Wnt-Fz-Rho pathway drive morphogenesis? Bioessays. 2011;33::759-68.

    Not in our library10.1002/bies.201100023

  112. 112.

    Muñoz-Descalzo S, Gómez-Cabrero A, Mlodzik M, Paricio N. Analysis of the role of the Rac/Cdc42 GTPases during planar cell polarity generation in Drosophila. Int J Dev Biol. 2007;51::379-87.

    Not in our library10.1387/ijdb.062250sm

  113. 113.

    Park E, Kim GH, Choi SC, Han JK. Role of PKA as a negative regulator of PCP signaling pathway during Xenopus gastrulation movements. Dev Biol. 2006;292::344-57.

    Not in our library10.1016/j.ydbio.2006.01.011

  114. 114.

    Kim GH, Han JK. JNK and ROKalpha function in the noncanonical Wnt/RhoA signaling pathway to regulate Xenopus convergent extension movements. Dev Dyn. 2005;232::958-68.

    Not in our library10.1002/dvdy.20262

  115. 115.

    De A. Wnt/Ca2 + signaling pathway: a brief overview. Acta Biochim Biophys Sin (Shanghai). 2011;43::745-56.

    Not in our library10.1093/abbs/gmr079

  116. 116.

    Zhuang X, Zhang H, Li X, Li X, Cong M, Peng F, et al. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol. 2017;19::1274-85.

    Not in our library10.1038/ncb3613

  117. 117.

    Flores-Hernández E, Velázquez DM, Castañeda-Patlán MC, Fuentes-García G, Fonseca-Camarillo G, Yamamoto-Furusho JK, et al. Canonical and non-canonical Wnt signaling are simultaneously activated by Wnts in colon cancer cells. Cell Signal. 2020;72::109636.

    Not in our library10.1016/j.cellsig.2020.109636

  118. 118.
  119. 119.

    Ma L, Wang HY. Mitogen-activated protein kinase p38 regulates the Wnt/cyclic GMP/Ca2 + non-canonical pathway. J Biol Chem. 2007;282::28980-90.

    Not in our library10.1074/jbc.m702840200

  120. 120.

    Wang H, Lee Y, Malbon CC. PDE6 is an effector for the Wnt/Ca2+/cGMP-signalling pathway in development. Biochem Soc Trans. 2004;32::792-6.

    Not in our library10.1042/bst0320792

  121. 121.

    Chen Y, Chen Z, Tang Y, Xiao Q. The involvement of noncanonical Wnt signaling in cancers. Biomed Pharmacother. 2021;133::110946.

    Not in our library10.1016/j.biopha.2020.110946

  122. 122.

    Burst HV. RCM Annual Meetings. New frontiers. Nurs Times. 1982;78:suppl 3–7.

    Not in our library

  123. 123.

    Malbon CC, Wang HY. Dishevelled: a mobile scaffold catalyzing development. Curr Top Dev Biol. 2006;72::153-66.

    Not in our library10.1016/s0070-2153(05)72002-0

  124. 124.

    Fiedler B, Wollert KC. Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc Res. 2004;63::450-7.

    Not in our library10.1016/j.cardiores.2004.04.002

  125. 125.

    Ma L, Wang HY. Suppression of cyclic GMP-dependent protein kinase is essential to the Wnt/cGMP/Ca2 + pathway. J Biol Chem. 2006;281::30990-1001.

    Not in our library10.1074/jbc.m603603200

  126. 126.

    Jiang X, Guan Y, Zhao Z, Meng F, Wang X, Gao X, et al. Potential Roles of the WNT Signaling Pathway in Amyotrophic Lateral Sclerosis. Cells 2021;10. 10.3390/cells10040839.

    Not in our library10.3390/cells10040839

  127. 127.

    Weerackoon N, Gunawardhana KL, Mani A. Wnt Signaling Cascades and Their Role in Coronary Artery Health and Disease. J Cell Signal. 2021;2:52-62.

    Not in our library10.33696/signaling.2.035

  128. 128.

    Fang N, Ding GW, Ding H, Li J, Liu C, Lv L, et al. Research Progress of Circular RNA in Gastrointestinal Tumors. Front Oncol. 2021;11::665246.

    Not in our library10.3389/fonc.2021.665246

  129. 129.

    Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495::384-8.

    Not in our library10.1038/nature11993

  130. 130.

    Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20::675-91.

    Not in our library10.1038/s41576-019-0158-7

  131. 131.

    Gao Y, Shang S, Guo S, Li X, Zhou H, Liu H, et al. Lnc2Cancer 3.0: an updated resource for experimentally supported lncRNA/circRNA cancer associations and web tools based on RNA-seq and scRNA-seq data. Nucleic Acids Res. 2021;49::D1251-d8.

    Not in our library10.1093/nar/gkaa1006

  132. 132.

    Patop IL, Wüst S, Kadener S. Past, present, and future of circRNAs. Embo j. 2019;38:e100836.

    Not in our library10.15252/embj.2018100836

  133. 133.

    Chen L, Wang C, Sun H, Wang J, Liang Y, Wang Y, et al. The bioinformatics toolbox for circRNA discovery and analysis. Brief Bioinform. 2021;22::1706-28.

    Not in our library10.1093/bib/bbaa001

  134. 134.
  135. 135.

    Aufiero S, Reckman YJ, Pinto YM, Creemers EE. Circular RNAs open a new chapter in cardiovascular biology. Nat Rev Cardiol. 2019;16:503-14.

    Not in our library10.1038/s41569-019-0185-2

  136. 136.

    Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56::55-66.

    Not in our library10.1016/j.molcel.2014.08.019

  137. 137.

    Eger N, Schoppe L, Schuster S, Laufs U, Boeckel JN. Circular RNA Splicing. Adv Exp Med Biol. 2018;1087::41-52.

    Not in our library10.1007/978-981-13-1426-1_4

  138. 138.

    Wilusz JE. A 360° view of circular RNAs: From biogenesis to functions. Wiley Interdiscip Rev RNA. 2018;9:e1478.

    Not in our library10.1002/wrna.1478

  139. 139.

    Pervouchine DD. Circular exonic RNAs: When RNA structure meets topology. Biochim Biophys Acta Gene Regul Mech. 2019;1862::194384.

    Not in our library10.1016/j.bbagrm.2019.05.002

  140. 140.

    Liu X, Hu Z, Zhou J, Tian C, Tian G, He M, et al. Interior circular RNA. RNA Biol. 2020;17:87-97.

    Not in our library10.1080/15476286.2019.1669391

  141. 141.

    Du WW, Zhang C, Yang W, Yong T, Awan FM, Yang BB. Identifying and Characterizing circRNA-Protein Interaction. Theranostics. 2017;7::4183-91.

    Not in our library10.7150/thno.21299

  142. 142.

    Zang J, Lu D, Xu A. The interaction of circRNAs and RNA binding proteins: An important part of circRNA maintenance and function. J Neurosci Res. 2020;98:87-97.

    Not in our library10.1002/jnr.24356

  143. 143.
  144. 144.

    Li X, Ding J, Wang X, Cheng Z, Zhu Q. NUDT21 regulates circRNA cyclization and ceRNA crosstalk in hepatocellular carcinoma. Oncogene. 2020;39:891-904.

    Not in our library10.1038/s41388-019-1030-0

  145. 145.
  146. 146.

    Li H, Xu JD, Fang XH, Zhu JN, Yang J, Pan R, et al. Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4. Cardiovasc Res. 2020;116::1323-34.

    Not in our library10.1093/cvr/cvz215

  147. 147.

    Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res. 2013;73::5609-12.

    Not in our library10.1158/0008-5472.can-13-1568

  148. 148.

    Yan L, Chen YG. Circular RNAs in Immune Response and Viral Infection. Trends Biochem Sci. 2020;45::1022-34.

    Not in our library10.1016/j.tibs.2020.08.006

  149. 149.
  150. 150.

    Su H, Zheng W, Pan J, Lv X, Xin S, Xu T, Circular RNA. circSamd4a Regulates Antiviral Immunity in Teleost Fish by Upregulating STING through Sponging miR-29a-3p. J Immunol. 2021;207::2770-84.

    Not in our library10.4049/jimmunol.2100469

  151. 151.

    Su H, Chu Q, Zheng W, Chang R, Gao W, Zhang L, et al. Circular RNA circPIKfyve acts as a sponge of miR-21-3p to enhance antiviral immunity through regulating MAVS in teleost fish. J Virol 2021;95. 10.1128/jvi.02296-20.

    Not in our library10.1128/jvi.02296-20

  152. 152.

    Zheng W, Chu Q, Yang L, Sun L, Xu T, Circular. RNA circDtx1 regulates IRF3-mediated antiviral immune responses through suppression of miR-15a-5p-dependent TRIF downregulation in teleost fish. PLoS Pathog. 2021;17:e1009438.

    Not in our library10.1371/journal.ppat.1009438

  153. 153.

    Wesselhoeft RA, Kowalski PS, Parker-Hale FC, Huang Y, Bisaria N, Anderson DG. RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo. Mol Cell 2019;74:508 – 20.e4. 10.1016/j.molcel.2019.02.015.

    Not in our library10.1016/j.molcel.2019.02.015

  154. 154.
  155. 155.

    Wang Y, Liu B. Circular RNA in Diseased Heart. Cells 2020;9. 10.3390/cells9051240.

    Not in our library10.3390/cells9051240

  156. 156.

    Wang J, Zhu S, Meng N, He Y, Lu R, Yan GR. ncRNA-Encoded Peptides or Proteins and Cancer. Mol Ther. 2019;27::1718-25.

    Not in our library10.1016/j.ymthe.2019.09.001

  157. 157.

    Wei Y, Zhang Y, Meng Q, Cui L, Xu C. Hypoxia-induced circular RNA has_circRNA_403658 promotes bladder cancer cell growth through activation of LDHA. Am J Transl Res. 2019;11:6838-49.

    Not in our library

  158. 158.

    Zhan W, Liao X, Chen Z, Li L, Tian T, Yu L, et al. Circular RNA hsa_circRNA_103809 promoted hepatocellular carcinoma development by regulating miR-377-3p/FGFR1/ERK axis. J Cell Physiol. 2020;235::1733-45.

    Not in our library10.1002/jcp.29092

  159. 159.

    Yang C, Han S. The circular RNA circ0005654 interacts with specificity protein 1 via microRNA-363 sequestration to promote gastric cancer progression. Bioengineered. 2021;12::6305-17.

    Not in our library10.1080/21655979.2021.1971031

  160. 160.

    Peng Y, Wang HH. Cir-ITCH inhibits gastric cancer migration, invasion and proliferation by regulating the Wnt/β-catenin pathway. Sci Rep. 2020;10::17443.

    Not in our library10.1038/s41598-020-74452-8

  161. 161.

    Liu WG, Xu Q. Upregulation of circHIPK3 promotes the progression of gastric cancer via Wnt/β-catenin pathway and indicates a poor prognosis. Eur Rev Med Pharmacol Sci. 2019;23::7905-12.

    Not in our library10.26355/eurrev_201909_19004

  162. 162.

    Yang L, Bi T, Zhou S, Lan Y, Zhang R. CircRASSF2 facilitates the proliferation and metastasis of colorectal cancer by mediating the activity of Wnt/β-catenin signaling pathway by regulating the miR-195-5p/FZD4 axis. Anticancer Drugs. 2021;32::919-29.

    Not in our library10.1097/cad.0000000000001084

  163. 163.

    Liu R, Deng P, Zhang Y, Wang Y, Peng C. Circ_0082182 promotes oncogenesis and metastasis of colorectal cancer in vitro and in vivo by sponging miR-411 and miR-1205 to activate the Wnt/β-catenin pathway. World J Surg Oncol. 2021;19::51.

    Not in our library10.1186/s12957-021-02164-y

  164. 164.

    Chen H, Pei L, Xie P, Guo G. Circ-PRKDC Contributes to 5-Fluorouracil Resistance of Colorectal Cancer Cells by Regulating miR-375/FOXM1 Axis and Wnt/β-Catenin Pathway. Onco Targets Ther. 2020;13::5939-53.

    Not in our library10.2147/ott.s253468

  165. 165.

    Ma Z, Han C, Xia W, Wang S, Li X, Fang P, et al. circ5615 functions as a ceRNA to promote colorectal cancer progression by upregulating TNKS. Cell Death Dis. 2020;11::356.

    Not in our library10.1038/s41419-020-2514-0

  166. 166.

    Li W, Xu Y, Wang X, Cao G, Bu W, Wang X, et al. circCCT3 Modulates Vascular Endothelial Growth Factor A and Wnt Signaling to Enhance Colorectal Cancer Metastasis Through Sponging miR-613. DNA Cell Biol. 2020;39::118-25.

    Not in our library10.1089/dna.2019.5139

  167. 167.

    Jin YD, Ren YR, Gao YX, Zhang L, Ding Z. Hsa_circ_0005075 predicts a poor prognosis and acts as an oncogene in colorectal cancer via activating Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 2019;23::3311-9.

    Not in our library10.26355/eurrev_201904_17693

  168. 168.

    Fang G, Ye BL, Hu BR, Ruan XJ, Shi YX. CircRNA_100290 promotes colorectal cancer progression through miR-516b-induced downregulation of FZD4 expression and Wnt/β-catenin signaling. Biochem Biophys Res Commun. 2018;504::184-9.

    Not in our library10.1016/j.bbrc.2018.08.152

  169. 169.

    Zhu P, Liang H, Huang X, Zeng Q, Liu Y, Lv J, et al. Circular RNA Hsa_circ_0004018 Inhibits Wnt/β-Catenin Signaling Pathway by Targeting microRNA-626/DKK3 in Hepatocellular Carcinoma. Onco Targets Ther. 2020;13::9351-64.

    Not in our library10.2147/ott.s254997

  170. 170.

    Chen H, Liu S, Li M, Huang P, Li X. circ_0003418 Inhibits Tumorigenesis And Cisplatin Chemoresistance Through Wnt/β-Catenin Pathway In Hepatocellular Carcinoma. Onco Targets Ther. 2019;12::9539-49.

    Not in our library10.2147/ott.s229507

  171. 171.

    Zhu YJ, Zheng B, Luo GJ, Ma XK, Lu XY, Lin XM, et al. Circular RNAs negatively regulate cancer stem cells by physically binding FMRP against CCAR1 complex in hepatocellular carcinoma. Theranostics. 2019;9::3526-40.

    Not in our library10.7150/thno.32796

  172. 172.

    Tan A, Li Q, Chen L. CircZFR promotes hepatocellular carcinoma progression through regulating miR-3619-5p/CTNNB1 axis and activating Wnt/β-catenin pathway. Arch Biochem Biophys. 2019;661:196-202.

    Not in our library10.1016/j.abb.2018.11.020

  173. 173.

    Zhu Q, Lu G, Luo Z, Gui F, Wu J, Zhang D, et al. CircRNA circ_0067934 promotes tumor growth and metastasis in hepatocellular carcinoma through regulation of miR-1324/FZD5/Wnt/β-catenin axis. Biochem Biophys Res Commun. 2018;497:626-32.

    Not in our library10.1016/j.bbrc.2018.02.119

  174. 174.

    Guo W, Zhang J, Zhang D, Cao S, Li G, Zhang S, et al. Polymorphisms and expression pattern of circular RNA circ-ITCH contributes to the carcinogenesis of hepatocellular carcinoma. Oncotarget. 2017;8:48169-77.

    Not in our library10.18632/oncotarget.18327

  175. 175.

    Li XY, Liu YR, Zhou JH, Li W, Guo HH, Ma HP. Enhanced expression of circular RNA hsa_circ_000984 promotes cells proliferation and metastasis in non-small cell lung cancer by modulating Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 2019;23::3366-74.

    Not in our library10.26355/eurrev_201904_17700

  176. 176.

    Ding L, Yao W, Lu J, Gong J, Zhang X. Upregulation of circ_001569 predicts poor prognosis and promotes cell proliferation in non-small cell lung cancer by regulating the Wnt/β-catenin pathway. Oncol Lett. 2018;16:453-8.

    Not in our library10.3892/ol.2018.8673

  177. 177.

    Yao Y, Hua Q, Zhou Y, Shen H. CircRNA has_circ_0001946 promotes cell growth in lung adenocarcinoma by regulating miR-135a-5p/SIRT1 axis and activating Wnt/β-catenin signaling pathway. Biomed Pharmacother. 2019;111::1367-75.

    Not in our library10.1016/j.biopha.2018.12.120

  178. 178.

    Yao Y, Zhou Y, Hua Q. circRNA hsa_circ_0018414 inhibits the progression of LUAD by sponging miR-6807-3p and upregulating DKK1. Mol Ther Nucleic Acids. 2021;23::783-96.

    Not in our library10.1016/j.omtn.2020.12.031

  179. 179.

    Yao Y, Hua Q, Zhou Y. CircRNA has_circ_0006427 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p/DKK1 axis and inactivating Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 2019;508:37-45.

    Not in our library10.1016/j.bbrc.2018.11.079

  180. 180.

    Gao S, Yu Y, Liu L, Meng J, Li G. Circular RNA hsa_circ_0007059 restrains proliferation and epithelial-mesenchymal transition in lung cancer cells via inhibiting microRNA-378. Life Sci. 2019;233::116692.

    Not in our library10.1016/j.lfs.2019.116692

  181. 181.
  182. 182.

    Lu Y, Deng X, Xiao G, Zheng X, Ma L, Huang W. circ_0001730 promotes proliferation and invasion via the miR-326/Wnt7B axis in glioma cells. Epigenomics. 2019;11::1335-52.

    Not in our library10.2217/epi-2019-0121

  183. 183.

    Chen Z, Duan X. hsa_circ_0000177-miR-638-FZD7-Wnt Signaling Cascade Contributes to the Malignant Behaviors in Glioma. DNA Cell Biol. 2018;37::791-7.

    Not in our library10.1089/dna.2018.4294

  184. 184.
  185. 185.

    Li Y, Liu J, Piao J, Ou J, Zhu X. Circ_0109046 promotes the malignancy of endometrial carcinoma cells through the microRNA-105/SOX9/Wnt/β-catenin axis. IUBMB Life. 2021;73::159-76.

    Not in our library10.1002/iub.2415

  186. 186.

    Shen Q, He T, Yuan H. Hsa_circ_0002577 promotes endometrial carcinoma progression via regulating miR-197/CTNND1 axis and activating Wnt/β-catenin pathway. Cell Cycle. 2019;18::1229-40.

    Not in our library10.1080/15384101.2019.1617004

  187. 187.

    Wu Z, Shi W, Jiang C. Overexpressing circular RNA hsa_circ_0002052 impairs osteosarcoma progression via inhibiting Wnt/β-catenin pathway by regulating miR-1205/APC2 axis. Biochem Biophys Res Commun. 2018;502::465-71.

    Not in our library10.1016/j.bbrc.2018.05.184

  188. 188.

    Wang M, Chen B, Ru Z, Cong L. CircRNA circ-ITCH suppresses papillary thyroid cancer progression through miR-22-3p/CBL/β-catenin pathway. Biochem Biophys Res Commun. 2018;504::283-8.

    Not in our library10.1016/j.bbrc.2018.08.175

  189. 189.

    Li Y, Wang Z, Su P, Liang Y, Li Z, Zhang H, et al. circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway. Mol Ther. 2022;30::415-30.

    Not in our library10.1016/j.ymthe.2021.08.026

  190. 190.

    Wang ST, Liu LB, Li XM, Wang YF, Xie PJ, Li Q, et al. Circ-ITCH regulates triple-negative breast cancer progression through the Wnt/β-catenin pathway. Neoplasma. 2019;66:232-9.

    Not in our library10.4149/neo_2018_180710n460

  191. 191.

    Zhang J, Xu HD, Xing XJ, Liang ZT, Xia ZH, Zhao Y. CircRNA_069718 promotes cell proliferation and invasion in triple-negative breast cancer by activating Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 2019;23::5315-22.

    Not in our library10.26355/eurrev_201906_18198

  192. 192.
  193. 193.
  194. 194.

    Hu J, Hu B, Deng L, Cheng L, Fan Q, Lu C. Arsenic sulfide inhibits the progression of gastric cancer through regulating the circRNA_ASAP2/Wnt/β-catenin pathway. Anticancer Drugs. 2022;33:e711-e9.

    Not in our library10.1097/cad.0000000000001246

  195. 195.

    He Y, Zhang Z, Wang Z, Jiao Y, Kang Q, Li J. Downregulation of circ-SFMBT2 blocks the development of gastric cancer by targeting the miR-885-3p/CHD7 pathway. Anticancer Drugs. 2022;33:e247-e59.

    Not in our library10.1097/cad.0000000000001195

  196. 196.

    Shi Q, Zhou C, Xie R, Li M, Shen P, Lu Y, et al. CircCNIH4 inhibits gastric cancer progression via regulating DKK2 and FRZB expression and Wnt/β-catenin pathway. J Biol Res (Thessalon). 2021;28:19.

    Not in our library10.1186/s40709-021-00140-x

  197. 197.

    Fang J, Chen W, Meng X. Downregulating circRNA_0044516 Inhibits Cell Proliferation in Gastric Cancer Through miR-149/Wnt1/β-catenin Pathway. J Gastrointest Surg. 2021;25::1696-705.

    Not in our library10.1007/s11605-020-04834-w

  198. 198.

    Sun H, Wang Q, Yuan G, Quan J, Dong D, Lun Y, et al. Hsa_circ_0001649 restrains gastric carcinoma growth and metastasis by downregulation of miR-20a. J Clin Lab Anal. 2020;34:e23235.

    Not in our library10.1002/jcla.23235

  199. 199.

    Gu H, Xu Z, Zhang J, Wei Y, Cheng L, Wang J. circ_0038718 promotes colon cancer cell malignant progression via the miR-195-5p/Axin2 signaling axis and also effect Wnt/β-catenin signal pathway. BMC Genomics. 2021;22::768.

    Not in our library10.1186/s12864-021-07880-z

  200. 200.

    Zhang X, Yao J, Shi H, Gao B, Zhou H, Zhang Y, et al. Hsa_circ_0026628 promotes the development of colorectal cancer by targeting SP1 to activate the Wnt/β-catenin pathway. Cell Death Dis. 2021;12::802.

    Not in our library10.1038/s41419-021-03794-6

  201. 201.

    Chen Z, Wu J, Liu B, Zhang G, Wang Z, Zhang L, et al. Identification of cis-HOX-HOXC10 axis as a therapeutic target for colorectal tumor-initiating cells without APC mutations. Cell Rep. 2021;36::109431.

    Not in our library10.1016/j.celrep.2021.109431

  202. 202.

    Yang S, Gao S, Liu T, Liu J, Zheng X, Li Z, Circular. RNA SMARCA5 functions as an anti-tumor candidate in colon cancer by sponging microRNA-552. Cell Cycle. 2021;20:689-701.

    Not in our library10.1080/15384101.2021.1899519

  203. 203.

    Zhang L, Dong X, Yan B, Yu W, Shan L. CircAGFG1 drives metastasis and stemness in colorectal cancer by modulating YY1/CTNNB1. Cell Death Dis. 2020;11::542.

    Not in our library10.1038/s41419-020-2707-6

  204. 204.

    Zhao H, Chen S, Fu Q. Exosomes from CD133(+) cells carrying circ-ABCC1 mediate cell stemness and metastasis in colorectal cancer. J Cell Biochem. 2020;121::3286-97.

    Not in our library10.1002/jcb.29600

  205. 205.

    Geng Y, Zheng X, Hu W, Wang Q, Xu Y, He W, et al. Hsa_circ_0009361 acts as the sponge of miR-582 to suppress colorectal cancer progression by regulating APC2 expression. Clin Sci (Lond). 2019;133::1197-213.

    Not in our library10.1042/cs20190286

  206. 206.

    Jin Y, Yu LL, Zhang B, Liu CF, Chen Y. Circular RNA hsa_circ_0000523 regulates the proliferation and apoptosis of colorectal cancer cells as miRNA sponge. Braz J Med Biol Res. 2018;51:e7811.

    Not in our library10.1590/1414-431x20187811

  207. 207.
  208. 208.

    Yang B, Zhao J, Huo T, Zhang M, Wu X. Effects of CircRNA-ITCH on proliferation and apoptosis of hepatocellular carcinoma cells through inhibiting Wnt/β-catenin signaling pathway. J buon. 2020;25:1368-74.

    Not in our library

  209. 209.

    Yang W, Liu Y, Gao R, Xiu Z, Sun T. Knockdown of cZNF292 suppressed hypoxic human hepatoma SMMC7721 cell proliferation, vasculogenic mimicry, and radioresistance. Cell Signal. 2019;60::122-35.

    Not in our library10.1016/j.cellsig.2019.04.011

  210. 210.
  211. 211.

    Yao X, Mao Y, Wu D, Zhu Y, Lu J, Huang Y, et al. Exosomal circ_0030167 derived from BM-MSCs inhibits the invasion, migration, proliferation and stemness of pancreatic cancer cells by sponging miR-338-5p and targeting the Wif1/Wnt8/β-catenin axis. Cancer Lett. 2021;512:38-50.

    Not in our library10.1016/j.canlet.2021.04.030

  212. 212.

    Xia D, Chen Z, Liu Q. Circ-PGC increases the expression of FOXR2 by targeting miR-532-3p to promote the development of non-small cell lung cancer. Cell Cycle. 2021;20:2195-209.

    Not in our library10.1080/15384101.2021.1974788

  213. 213.

    Gao F, Jia L, Han J, Wang Y, Luo W, Zeng Y. Circ-ZNF124 downregulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/β-catenin signaling pathway via mediating the miR-498/YES1 axis. Anticancer Drugs. 2021;32::257-68.

    Not in our library10.1097/cad.0000000000001014

  214. 214.

    Jin Z, Gao B, Gong Y, Guan L. Depletion of circ-BIRC6, a circular RNA, suppresses non-small cell lung cancer progression by targeting miR-4491. Biosci Trends. 2021;14:399-407.

    Not in our library10.5582/bst.2020.03310

  215. 215.

    Zhao M, Ma W, Ma C. Circ_0067934 promotes non-small cell lung cancer development by regulating miR-1182/KLF8 axis and activating Wnt/β-catenin pathway. Biomed Pharmacother. 2020;129::110461.

    Not in our library10.1016/j.biopha.2020.110461

  216. 216.

    Tian F, Yu CT, Ye WD, Wang Q. Cinnamaldehyde induces cell apoptosis mediated by a novel circular RNA hsa_circ_0043256 in non-small cell lung cancer. Biochem Biophys Res Commun. 2017;493::1260-6.

    Not in our library10.1016/j.bbrc.2017.09.136

  217. 217.
  218. 218.
  219. 219.

    Li S, Yu C, Zhang Y, Liu J, Jia Y, Sun F, et al. Circular RNA cir-ITCH Is a Potential Therapeutic Target for the Treatment of Castration-Resistant Prostate Cancer. Biomed Res Int. 2020;2020::7586521.

    Not in our library10.1155/2020/7586521

  220. 220.

    Lin X, Chen Y, Ye X, Xia X. Circular. RNA ABCB10 promotes cell proliferation and invasion, but inhibits apoptosis via regulating the microRNA–1271–mediated Capn4/Wnt/β–catenin signaling pathway in epithelial ovarian cancer. Mol Med Rep. 2021;23. 10.3892/mmr.2021.12026.

    Not in our library10.3892/mmr.2021.12026

  221. 221.

    Pan Q, Meng X, Li J, Qin X, Chen H, Li Y. CircSAMD11 facilitates progression of cervical cancer via regulating miR-503/SOX4 axis through Wnt/β-catenin pathway. Clin Exp Pharmacol Physiol. 2022;49:175-87.

    Not in our library10.1111/1440-1681.13593

  222. 222.

    Chen JJ, Lei P, Zhou M. hsa_circ_0121582 inhibits leukemia growth by dampening Wnt/β-catenin signaling. Clin Transl Oncol. 2020;22::2293-302.

    Not in our library10.1007/s12094-020-02377-9

  223. 223.

    Xia L, Wu L, Bao J, Li Q, Chen X, Xia H, et al. Circular RNA circ-CBFB promotes proliferation and inhibits apoptosis in chronic lymphocytic leukemia through regulating miR-607/FZD3/Wnt/β-catenin pathway. Biochem Biophys Res Commun. 2018;503:385-90.

    Not in our library10.1016/j.bbrc.2018.06.045

  224. 224.

    Hu Y, Zhao Y, Shi C, Ren P, Wei B, Guo Y, et al. A circular RNA from APC inhibits the proliferation of diffuse large B-cell lymphoma by inactivating Wnt/β-catenin signaling via interacting with TET1 and miR-888. Aging (Albany NY). 2019;11::8068-84.

    Not in our library10.18632/aging.102122

  225. 225.

    Gong X, Li W, Dong L, Qu F. CircUBAP2 promotes SEMA6D expression to enhance the cisplatin resistance in osteosarcoma through sponging miR-506-3p by activating Wnt/β-catenin signaling pathway. J Mol Histol. 2020;51::329-40.

    Not in our library10.1007/s10735-020-09883-8

  226. 226.
  227. 227.

    Chen F, Feng Z, Zhu J, Liu P, Yang C, Huang R, et al. Emerging roles of circRNA_NEK6 targeting miR-370-3p in the proliferation and invasion of thyroid cancer via Wnt signaling pathway. Cancer Biol Ther. 2018;19::1139-52.

    Not in our library10.1080/15384047.2018.1480888

  228. 228.

    Wu H, Xu J, Gong G, Zhang Y, Wu S. CircARL8B Contributes to the Development of Breast Cancer Via Regulating miR-653-5p/HMGA2 Axis. Biochem Genet. 2021;59::1648-65.

    Not in our library10.1007/s10528-021-10082-7

  229. 229.

    Jiang J, Cheng X, Circular RNA. circABCC4 acts as a ceRNA of miR-154-5p to improve cell viability, migration and invasion of breast cancer cells in vitro. Cell Cycle. 2020;19::2653-61.

    Not in our library10.1080/15384101.2020.1815147

  230. 230.

    Yao Y, Li X, Cheng L, Wu X, Wu B. Circular RNA FAT atypical cadherin 1 (circFAT1)/microRNA-525-5p/spindle and kinetochore-associated complex subunit 1 (SKA1) axis regulates oxaliplatin resistance in breast cancer by activating the notch and Wnt signaling pathway. Bioengineered. 2021;12::4032-43.

    Not in our library10.1080/21655979.2021.1951929

  231. 231.

    Liu S, Chen L, Chen H, Xu K, Peng X, Zhang M. Circ_0119872 promotes uveal melanoma development by regulating the miR-622/G3BP1 axis and downstream signalling pathways. J Exp Clin Cancer Res. 2021;40::66.

    Not in our library10.1186/s13046-021-01833-w

  232. 232.

    Chen J, Zhou X, Yang J, Sun Q, Liu Y, Li N, et al. Circ-GLI1 promotes metastasis in melanoma through interacting with p70S6K2 to activate Hedgehog/GLI1 and Wnt/β-catenin pathways and upregulate Cyr61. Cell Death Dis. 2020;11::596.

    Not in our library10.1038/s41419-020-02799-x

  233. 233.

    Chen Z, Chen J, Wa Q, He M, Wang X, Zhou J, et al. Knockdown of circ_0084043 suppresses the development of human melanoma cells through miR-429/tribbles homolog 2 axis and Wnt/β-catenin pathway. Life Sci. 2020;243::117323.

    Not in our library10.1016/j.lfs.2020.117323

  234. 234.
  235. 235.

    Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol. 2020;12::1758835920927602.

    Not in our library10.1177/1758835920927602

  236. 236.

    Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R, et al. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. J Clin Med 2019;8. 10.3390/jcm8010055.

    Not in our library10.3390/jcm8010055

  237. 237.
  238. 238.

    Sasaki R, Kanda T, Fujisawa M, Matsumoto N, Masuzaki R, Ogawa M, et al. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines. Int J Mol Sci 2020;21. 10.3390/ijms21093349.

    Not in our library10.3390/ijms21093349

  239. 239.

    Chen CH, Su YJ, Ding H, Duan J, Wang J, Circular. RNA ZNF292 affects proliferation and apoptosis of hepatocellular carcinoma cells by regulating Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 2020;24::12124-30.

    Not in our library10.26355/eurrev_202012_24001

  240. 240.

    Wang C, Zhang T, Liao Q, Dai M, Guo J, Yang X, et al. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Protein Cell. 2021;12::128-44.

    Not in our library10.1007/s13238-020-00760-4

  241. 241.

    Bibok A, Kim DW, Malafa M, Kis B. Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer. World J Gastroenterol. 2021;27::4322-41.

    Not in our library10.3748/wjg.v27.i27.4322

  242. 242.

    Iglesia D, Avci B, Kiriukova M, Panic N, Bozhychko M, Sandru V, et al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis. United Eur Gastroenterol J. 2020;8::1115-25.

    Not in our library10.1177/2050640620938987

  243. 243.

    Bushnell GG, Orbach SM, Ma JA, Crawford HC, Wicha MS, Jeruss JS, et al. Disease-induced immunomodulation at biomaterial scaffolds detects early pancreatic cancer in a spontaneous model. Biomaterials. 2021;269:120632.

    Not in our library10.1016/j.biomaterials.2020.120632

  244. 244.

    Li L, Bao J, Wang H, Lei JH, Peng C, Zeng J, et al. Upregulation of amplified in breast cancer 1 contributes to pancreatic ductal adenocarcinoma progression and vulnerability to blockage of hedgehog activation. Theranostics. 2021;11::1672-89.

    Not in our library10.7150/thno.47390

  245. 245.

    Elaskalani O, Domenichini A, Abdol Razak NB, D ED, Falasca M, Metharom P. Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells. Cancers (Basel). 2020;12. 10.3390/cancers12010250.

    Not in our library10.3390/cancers12010250

  246. 246.

    O’Reilly EM, Hechtman JF. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol. 2019;30:viii36-40.

    Not in our library10.1093/annonc/mdz385

  247. 247.

    Zhang Q, Wang JY, Zhou SY, Yang SJ, Zhong SL. Circular RNA expression in pancreatic ductal adenocarcinoma. Oncol Lett. 2019;18::2923-30.

    Not in our library10.3892/ol.2019.10624

  248. 248.

    Khan N, Mukhtar H. Dietary agents for prevention and treatment of lung cancer. Cancer Lett. 2015;359:155-64.

    Not in our library10.1016/j.canlet.2015.01.038

  249. 249.

    Zha JH, Xia YC, Ye CL, Hu Z, Zhang Q, Xiao H, et al. The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620. Front Oncol. 2021;11::669518.

    Not in our library10.3389/fonc.2021.669518

  250. 250.

    Teng K, Zhang Y, Hu X, Ding Y, Gong R, Liu L. Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair. Onco Targets Ther. 2015;8::809-18.

    Not in our library10.2147/ott.s77283

  251. 251.

    Lin L, Zhao J, Hu J, Huang F, Han J, He Y, et al. Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience. Onco Targets Ther. 2016;9::6305-14.

    Not in our library10.2147/ott.s113374

  252. 252.
  253. 253.

    Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16::e165-72.

    Not in our library10.1016/s1470-2045(14)71180-5

  254. 254.
  255. 255.

    Wahab A, Kesari K, Chaudhary S, Khan M, Khan H, Smith S, et al. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation? Cancer Biol Ther. 2017;18::940-3.

    Not in our library10.1080/15384047.2017.1394546

  256. 256.

    Sun X, Turcan S. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. Cells 2021;10. 10.3390/cells10051225.

    Not in our library10.3390/cells10051225

  257. 257.

    Sturm D, Pfister SM, Jones DTW. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. J Clin Oncol. 2017;35::2370-7.

    Not in our library10.1200/jco.2017.73.0242

  258. 258.

    Groblewska M, Litman-Zawadzka A, Mroczko B. The Role of Selected Chemokines and Their Receptors in the Development of Gliomas. Int J Mol Sci 2020;21. 10.3390/ijms21103704.

    Not in our library10.3390/ijms21103704

  259. 259.

    Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16:896-913.

    Not in our library10.1093/neuonc/nou087

  260. 260.

    Ding C, Yi X, Wu X, Bu X, Wang D, Wu Z, et al. Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma. Cancer Lett. 2020;479::1-12.

    Not in our library10.1016/j.canlet.2020.03.002

  261. 261.
  262. 262.
  263. 263.
  264. 264.

    Du Q, Zhang W, Feng Q, Hao B, Cheng C, Cheng Y, et al. Comprehensive circular RNA profiling reveals that hsa_circ_0001368 is involved in growth hormone-secreting pituitary adenoma development. Brain Res Bull. 2020;161:65-77.

    Not in our library10.1016/j.brainresbull.2020.04.018

  265. 265.
  266. 266.

    Chen K, Xu H, Zhao J. Bloom Syndrome Protein Activates AKT and PRAS40 in Prostate Cancer Cells. Oxid Med Cell Longev. 2019;2019::3685817.

    Not in our library10.1155/2019/3685817

  267. 267.

    Mollica V, Di Nunno V, Cimadamore A, Lopez-Beltran A, Cheng L, Santoni M, et al. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. Cells 2019;8. 10.3390/cells8010043.

    Not in our library10.3390/cells8010043

  268. 268.
  269. 269.

    Wang L, Liu X, Liu Z, Wang Y, Fan M, Yin J, et al. Network models of prostate cancer immune microenvironments identify ROMO1 as heterogeneity and prognostic marker. Sci Rep. 2022;12::192.

    Not in our library10.1038/s41598-021-03946-w

  270. 270.
  271. 271.

    Farrand L, Oh SW, Song YS, Tsang BK. Phytochemicals: a multitargeted approach to gynecologic cancer therapy. Biomed Res Int. 2014;2014::890141.

    Not in our library10.1155/2014/890141

  272. 272.

    Wang G, Liu X, Wang D, Sun M, Yang Q. Identification and Development of Subtypes With Poor Prognosis in Pan-Gynecological Cancer Based on Gene Expression in the Glycolysis-Cholesterol Synthesis Axis. Front Oncol. 2021;11::636565.

    Not in our library10.3389/fonc.2021.636565

  273. 273.

    Zhang H, Wang S, Cacalano N, Zhu H, Liu Q, Xie M, et al. Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines. Sci Rep. 2019;9::2111.

    Not in our library10.1038/s41598-019-38585-9

  274. 274.

    Li C, Ao H, Chen G, Wang F, Li F. The Interaction of CDH20 With β-Catenin Inhibits Cervical Cancer Cell Migration and Invasion via TGF-β/Smad/SNAIL Mediated EMT. Front Oncol. 2019;9::1481.

    Not in our library10.3389/fonc.2019.01481

  275. 275.

    Li T, Yang Z, Jiang S, Di W, Ma Z, Hu W, et al. Melatonin: does it have utility in the treatment of haematological neoplasms? Br J Pharmacol. 2018;175::3251-62.

    Not in our library10.1111/bph.13966

  276. 276.

    Howell DA, Wang HI, Roman E, Smith AG, Patmore R, Johnson MJ, et al. Preferred and actual place of death in haematological malignancy. BMJ Support Palliat Care. 2017;7::150-7.

    Not in our library10.1136/bmjspcare-2014-000793

  277. 277.

    Auberger P, Tamburini-Bonnefoy J, Puissant A. Drug Resistance in Hematological Malignancies. Int J Mol Sci 2020;21. 10.3390/ijms21176091.

    Not in our library10.3390/ijms21176091

  278. 278.

    Deshantri AK, Varela Moreira A, Ecker V, Mandhane SN, Schiffelers RM, Buchner M, et al. Nanomedicines for the treatment of hematological malignancies. J Control Release. 2018;287:194-215.

    Not in our library10.1016/j.jconrel.2018.08.034

  279. 279.

    Jin MW, Xu SM, An Q, Wang P. A review of risk factors for childhood leukemia. Eur Rev Med Pharmacol Sci. 2016;20:3760-4.

    Not in our library

  280. 280.

    Li AJ, Dhanraj JP, Lopes G, Parker JL. Clinical trial risk in leukemia: Biomarkers and trial design. Hematol Oncol. 2021;39::105-13.

    Not in our library10.1002/hon.2818

  281. 281.

    Zhao H, Wang D, Du W, Gu D, Yang R. MicroRNA and leukemia: tiny molecule, great function. Crit Rev Oncol Hematol. 2010;74::149-55.

    Not in our library10.1016/j.critrevonc.2009.05.001

  282. 282.

    Morelli MB, Liberati S, Amantini C, Nabiss M, Santoni M, Farfariello V, et al. Expression and function of the transient receptor potential ion channel family in the hematologic malignancies. Curr Mol Pharmacol. 2013;6::137-48.

    Not in our library10.2174/187446720603140415215431

  283. 283.

    Battistello E, Katanayeva N, Dheilly E, Tavernari D, Donaldson MC, Bonsignore L, et al. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. Blood. 2018;131::2345-56.

    Not in our library10.1182/blood-2017-10-809210

  284. 284.

    Zhu J, Yang Y, Tao J, Wang SL, Chen B, Dai JR, et al. Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. Leukemia. 2020;34:2576-91.

    Not in our library10.1038/s41375-020-0963-1

  285. 285.

    Caramuta S, Lee L, Ozata DM, Akçakaya P, Georgii-Hemming P, Xie H, et al. Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. Blood Cancer J. 2013;3:e152.

    Not in our library10.1038/bcj.2013.49

  286. 286.

    Mateu-Sanz M, Tornín J, Brulin B, Khlyustova A, Ginebra MP, Layrolle P, et al. Cold Plasma-Treated Ringer’s Saline: A Weapon to Target Osteosarcoma. Cancers (Basel). 2020;12. 10.3390/cancers12010227.

    Not in our library10.3390/cancers12010227

  287. 287.

    Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children’s Cancer Group, Pediatric Oncology Group, and Children’s Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016;34::3031-8.

    Not in our library10.1200/jco.2015.65.5381

  288. 288.

    Lallier M, Marchandet L, Moukengue B, Charrier C, Baud’huin M, Verrecchia F, et al. Molecular Chaperones in Osteosarcoma: Diagnosis and Therapeutic Issues. Cells 2021;10. 10.3390/cells10040754.

    Not in our library10.3390/cells10040754

  289. 289.
  290. 290.

    Li C, Cai J, Ge F, Wang G. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma. Int J Mol Med. 2018;42::1799-808.

    Not in our library10.3892/ijmm.2018.3753

  291. 291.

    Wen JF, Jiang YQ, Li C, Dai XK, Wu T, Yin WZ. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2. Cancer Biomark. 2020;28::231-46.

    Not in our library10.3233/cbm-191181

  292. 292.

    Yong L, Ma Y, Liang C, He G, Zhao Z, Yang C, et al. Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1. Phytother Res. 2019;33::1837-50.

    Not in our library10.1002/ptr.6373

  293. 293.
  294. 294.

    Yang D, Xu T, Fan L, Liu K, Li G. microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis. J Exp Clin Cancer Res. 2020;39::201.

    Not in our library10.1186/s13046-020-01670-3

  295. 295.

    Zhang L, Wang Y, Li X, Xia X, Li N, He R, et al. ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing lncRNALINC00473-IL24 Activity. Neoplasia. 2017;19::908-18.

    Not in our library10.1016/j.neo.2017.08.008

  296. 296.
  297. 297.

    Yang Z, Wei X, Pan Y, Xu J, Si Y, Min Z, et al. A new risk factor indicator for papillary thyroid cancer based on immune infiltration. Cell Death Dis. 2021;12::51.

    Not in our library10.1038/s41419-020-03294-z

  298. 298.

    Cao Y, Zhong X, Diao W, Mu J, Cheng Y, Jia Z. Radiomics in Differentiated Thyroid Cancer and Nodules: Explorations, Application, and Limitations. Cancers (Basel). 2021;13. 10.3390/cancers13102436.

    Not in our library10.3390/cancers13102436

  299. 299.

    Xu B, Ibrahimpasic T, Wang L, Sabra MM, Migliacci JC, Tuttle RM, et al. Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. Thyroid. 2016;26:1588-97.

    Not in our library10.1089/thy.2016.0247

  300. 300.

    Loehrer AP, Murthy SS, Song Z, Lubitz CC, James BC. Association of Insurance Expansion With Surgical Management of Thyroid Cancer. JAMA Surg. 2017;152::734-40.

    Not in our library10.1001/jamasurg.2017.0461

  301. 301.

    Li S, Chen C, Xiong X, Huang Y, Hu J, Fan Z, et al. Type Iγ phosphatidylinositol phosphate kinase dependent cell migration and invasion are dispensable for tumor metastasis. Am J Cancer Res. 2019;9::959-74.

    Not in our library

  302. 302.

    Hu PC, Li K, Tian YH, Pan WT, Wang Y, Xu XL, et al. CREB1/Lin28/miR-638/VASP Interactive Network Drives the Development of Breast Cancer. Int J Biol Sci. 2019;15::2733-49.

    Not in our library10.7150/ijbs.36854

  303. 303.

    Chen Y, Chen L, Zhang JY, Chen ZY, Liu TT, Zhang YY, et al. Oxymatrine reverses epithelial-mesenchymal transition in breast cancer cells by depressing α(V)β(3) integrin/FAK/PI3K/Akt signaling activation. Onco Targets Ther. 2019;12::6253-65.

    Not in our library10.2147/ott.s209056

  304. 304.

    Chen H, Sun Y, Yang Z, Yin S, Li Y, Tang M, et al. Metabolic heterogeneity and immunocompetence of infiltrating immune cells in the breast cancer microenvironment (Review). Oncol Rep. 2021;45::846-56.

    Not in our library10.3892/or.2021.7946

  305. 305.

    Colombino M, Paliogiannis P, Cossu A, De Re V, Miolo G, Botti G, et al. BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. J Clin Med 2019;8. 10.3390/jcm8101577.

    Not in our library10.3390/jcm8101577

  306. 306.

    Katsarelias D, Eriksson H, Mikiver R, Krakowski I, Nilsson JA, Ny L, et al. The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma-A Nation-Wide Swedish Population-Based Retrospective Register Study. Cancers (Basel). 2020;12. 10.3390/cancers12113228.

    Not in our library10.3390/cancers12113228

  307. 307.

    Vogelsang M, Wilson M, Kirchhoff T. Germline determinants of clinical outcome of cutaneous melanoma. Pigment Cell Melanoma Res. 2016;29:15-26.

    Not in our library10.1111/pcmr.12418

  308. 308.

    Kwiatkowska-Borowczyk E, Czerwińska P, Mackiewicz J, Gryska K, Kazimierczak U, Tomela K, et al. Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients. Oncoimmunology. 2018;7:e1509821.

    Not in our library10.1080/2162402x.2018.1509821

  309. 309.

    Tang L, Long J, Li K, Zhang X, Chen X, Peng C. A novel chalcone derivative suppresses melanoma cell growth through targeting Fyn/Stat3 pathway. Cancer Cell Int. 2020;20::256.

    Not in our library10.1186/s12935-020-01336-2

  310. 310.

    Zhang Y, Ma JA, Zhang HX, Jiang YN, Luo WH. Cancer vaccines: Targeting KRAS-driven cancers. Expert Rev Vaccines. 2020;19::163-73.

    Not in our library10.1080/14760584.2020.1733420

  311. 311.

    Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. Clin Cancer Res. 2018;24::266-75.

    Not in our library10.1158/1078-0432.ccr-17-1117

  312. 312.

    Maida M, Macaluso FS, Ianiro G, Mangiola F, Sinagra E, Hold G, et al. Screening of colorectal cancer: present and future. Expert Rev Anticancer Ther. 2017;17::1131-46.

    Not in our library10.1080/14737140.2017.1392243

  313. 313.

    Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ. Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol. 2016;13::550-65.

    Not in our library10.1038/nrclinonc.2016.50

  314. 314.

    Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR. Early detection and screening of lung cancer. Expert Rev Mol Diagn. 2010;10:799-815.

    Not in our library10.1586/erm.10.60

  315. 315.

    Tian JY, Guo FJ, Zheng GY, Ahmad A. Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities. Carcinogenesis. 2018;39::307-17.

    Not in our library10.1093/carcin/bgx141

  316. 316.

    Greenwald ZR, El-Zein M, Bouten S, Ensha H, Vazquez FL, Franco EL. Mobile Screening Units for the Early Detection of Cancer: A Systematic Review. Cancer Epidemiol Biomarkers Prev. 2017;26::1679-94.

    Not in our library10.1158/1055-9965.epi-17-0454

  317. 317.

    Lindquist D, Kvarnbrink S, Henriksson R, Hedman H. LRIG and cancer prognosis. Acta Oncol. 2014;53::1135-42.

    Not in our library10.3109/0284186x.2014.953258

  318. 318.

    Sidders B, Zhang P, Goodwin K, O’Connor G, Russell DL, Borodovsky A, et al. Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response. Clin Cancer Res. 2020;26::2176-87.

    Not in our library10.1158/1078-0432.ccr-19-2183

  319. 319.

    Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, et al. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. J Clin Oncol. 2020;38::725-33.

    Not in our library10.1200/jco.19.01959

  320. 320.

    Cobain EF, Hayes DF. Indications for prognostic gene expression profiling in early breast cancer. Curr Treat Options Oncol. 2015;16:23.

    Not in our library10.1007/s11864-015-0340-x

  321. 321.

    Paulsson J, Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol. 2014;25::61-8.

    Not in our library10.1016/j.semcancer.2014.02.006

  322. 322.
  323. 323.

    Hua JT, Chen S, He HH. Landscape of Noncoding RNA in Prostate Cancer. Trends Genet. 2019;35::840-51.

    Not in our library10.1016/j.tig.2019.08.004

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.